Diagnostics company Nutromics has raised $7M in pre-series A funding. The company has been actively raising funds in preparation for the upcoming commercialisation of its continuous diagnostic monitoring technology.
Nutromics, founded in 2017, has been focused on the development of a cutting-edge "lab-in-a-patch" technology. This innovative approach utilises DNA sensor technology to monitor various targets within the human body, including disease biomarkers and drugs with challenging dosage requirements. Currently, the technology is undergoing an in-human trial at Monash Health to evaluate its effectiveness.
In addition to clinical trials, Nutromics is establishing dedicated research and development teams in both Australia and the United States, further enhancing its capabilities and expanding its reach.
The latest funding follows a strategic investment from Dexcom Ventures and other VC firms last year, worth $14M. Nutromics will launch a Series A funding round later this year, aiming to raise approximately $33M in investments.
Click here to read the original news story.